New Strategies for Advanced Neuroendocrine Tumors in the Era of Targeted Therapy
New Strategies for Advanced Neuroendocrine Tumors in the Era of Targeted Therapy
复制标题
DOI：
10.1158/1078-0432.ccr-11-2105
复制
发表时间：
2012-04-01
影响因子：
11.5
通讯作者：
Yao, James C.
中科院分区：
文献类型：
--
作者：
Dong, Mei;Phan, Alexandria T.;Yao, James C.
低度至中度神经内分泌肿瘤（NET）是一组具有分泌激素和神经胺能力的惰性恶性肿瘤。直到最近，肿瘤控制的治疗选择很少。PROMID研究表明，奥曲肽长效可重复制剂可延迟中肠NET中的肿瘤生长。而且，最近的III期研究表明依维莫司和舒尼替尼都能改善胰腺NET的无进展生存期，验证了磷酸肌醇3-激酶/Akt/mTOR通路和血管生成是进一步发展的重要靶点。针对其他NET亚型中这些通路的正在进行和计划中的关键性研究可能会扩大其治疗应用。合理组合的开发可能会进一步改善治疗结果。这些成功和我们对潜在分子生物学的更好理解可能会导致进一步的重要进展。Clin Cancer Res; 18（7）; 1830-6. (C)2012年AACR。
Low-to intermediate-grade neuroendocrine tumor (NET) constitutes a group of indolent malignancies that share the capacity for secreting hormones and neuroamines. Until recently, there were few therapeutic options for oncologic control. The PROMID study showed that octreotide long-acting repeatable formulation can delay tumor growth in midgut NETs. And, recent phase III studies showed both everolimus and sunitinib improved progression-free survival in pancreatic NETs, validating the phosphoinositide 3-kinase/Akt/mTOR pathway and angiogenesis as important targets for further advances. Ongoing and planned pivotal studies targeting these pathways in other NET subtypes may widen their therapeutic application. Development of rational combinations may further improve therapeutic outcome. These successes and our improved understanding of the underlying molecular biology are likely to lead to further important advances on the horizon. Clin Cancer Res; 18(7); 1830-6. (C) 2012 AACR.